Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule

• Published in: FEMS immunology and medical microbiology 2003-07, Vol.37 (2), p.167-171
• Main Authors: Göcke, Kerstin, Baumann, Ulrich, Hagemann, Hartmut, Gabelsberger, Josef, Hahn, Heinz, Freihorst, Joachim, von Specht, Bernd Ulrich
• Format: Article
• Language: English
• Subjects: Administration, Intranasal; Adult; Antibodies, Bacterial - blood; Bacterial Proteins - genetics; Bacterial Proteins - immunology; Bacterial Vaccines - administration & dosage; Bacterial Vaccines - immunology; Bacteriology; Biological and medical sciences; Fundamental and applied biological sciences. Psychology; Humans; Immunization Schedule; Immunization, Secondary; Immunoglobulin G - blood; Lipoproteins - genetics; Lipoproteins - immunology; Men; Microbiology; Mucosal vaccination; Porins - genetics; Porins - immunology; Pseudomonas aeruginosa; Pseudomonas aeruginosa - immunology; Pseudomonas Infections - immunology; Pseudomonas Infections - prevention & control; Recombinant Fusion Proteins - genetics; Recombinant Fusion Proteins - immunology; Serum antibody; Systemic booster; Vaccination; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - immunology
• ISSN: 0928-8244; 1574-695X
• DOI: 10.1016/S0928-8244(03)00094-4

We compared the immunogenicity of two vaccination schedules with either a systemic or a mucosal booster, both following a mucosal primary vaccination with a recombinant outer membrane fusion protein of Pseudomonas aeruginosa (OprF-I) in 12 healthy volunteers. The systemic booster induced higher levels of OprF-I-specific serum antibodies of IgG isotype, with a mean±S.E.M. of 32.6±7.8×10 7 enzyme-linked immunosorbent assay (ELISA) units (EU) as compared to the nasal booster with 14.6±2.1×10 7 EU ( P=0.05). Specific serum IgA antibodies and antibodies in saliva did not differ between the two vaccination groups. We conclude that a combined mucosal/systemic vaccination with the OprF-I vaccine may offer an enhanced systemic immunogenicity. Further studies on the long-term immunogenicity and induction of antibodies on the respiratory airway surface are warranted.